Solvotrin Therapeutics Management

Solvotrin Therapeutics was founded in 2009 by Pat O’Flynn, Dr John Gilmer and Dr Mark Ledwidge with the goal to become a global leader in identifying and addressing unmet clinical needs in blockbuster and nichebuster cardiovascular and cancer markets:

Pat O’Flynn: President and Chief Executive Officer

Dr. John Gilmer: Vice President Research and Development

Dr. Mark Ledwidge: Vice President Development and Strategy

John O’Flynn: Non-Executive Director

Scientific & Medical Advisory Board

Dr. Eugenio A. Cefali: Former Vice President of Lead Optimization at Kos Pharmaceuticals and played a major role in the development of Niaspan®

Professor Michael Berndt: Director of The Biomedical Diagnostics Institute, Dublin, Ireland

Professor Damian O’Connell: Senior Vice President and Head of Clinical Pharmacology and Experimental and Translational Medicine at Bayer in Germany

Professor David Kerins: Consultant Physician at Mercy University Hospital, Cork, Ireland

Professor Marek Radomski: Director of Research in the School of Pharmacy and Head of School and Pro-Dean of the Faculty of Health Sciences, Trinity College, Dublin, Ireland

The Company is managed by an experienced management team with an extensive and proven track record focused on drug development for the global pharmaceuticals market.